NASDAQ:FDMT 4D Molecular Therapeutics Q4 2024 Earnings Report $14.47 -0.24 (-1.63%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$14.46 -0.02 (-0.10%) As of 09/25/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast 4D Molecular Therapeutics EPS ResultsActual EPS-$0.90Consensus EPS -$0.80Beat/MissMissed by -$0.10One Year Ago EPSN/A4D Molecular Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$2.28 millionBeat/MissN/AYoY Revenue GrowthN/A4D Molecular Therapeutics Announcement DetailsQuarterQ4 2024Date2/28/2025TimeBefore Market OpensConference Call DateFriday, February 28, 2025Conference Call Time4:00PM ETUpcoming Earnings4D Molecular Therapeutics' Q3 2026 earnings is estimated for Tuesday, November 10, 2026, based on past reporting schedules, with a conference call scheduled on Monday, November 9, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) 4D Molecular Therapeutics Earnings Headlines4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $22,317.75 in StockSeptember 25 at 5:09 AM | americanbankingnews.com4D Molecular Therapeutics, Inc. (FDMT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference TranscriptSeptember 17, 2026 | seekingalpha.comCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.September 26 at 1:00 AM | Paradigm Press (Ad)4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Up 7.3% on Analyst UpgradeSeptember 16, 2026 | americanbankingnews.com4D Molecular Therapeutics (NASDAQ:FDMT) Stock Rating Upgraded by Cantor FitzgeraldSeptember 16, 2026 | americanbankingnews.com4D Molecular Therapeutics, Inc. (FDMT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 14, 2026 | seekingalpha.comSee More 4D Molecular Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like 4D Molecular Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 4D Molecular Therapeutics and other key companies, straight to your email. Email Address About 4D Molecular Therapeutics4D Molecular Therapeutics (NASDAQ:FDMT) is a clinical-stage biotechnology company developing genetic medicines for serious diseases with significant unmet medical needs. The company uses its Therapeutic Vector Evolution platform to engineer and select adeno-associated virus (AAV) vectors designed to deliver genetic payloads to specific tissues and support the development of potentially durable, one-time treatments. Its research and development programs have focused primarily on ophthalmic and pulmonary diseases. The company’s pipeline has included investigational gene therapies for retinal conditions such as wet age-related macular degeneration and diabetic macular edema, as well as programs intended to address diseases including cystic fibrosis and Fabry disease. Development programs and indications may change as clinical research progresses. Founded in 2013 and headquartered in Emeryville, California, 4D Molecular Therapeutics became a publicly traded company in 2020. The company was co-founded by David Kirn, M.D., who has served as its chief executive officer and has played a central role in its gene therapy research and corporate development. Its products remain investigational and are subject to clinical testing and regulatory review.View 4D Molecular Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/21 - 09/25Costco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic ProblemDarden Restaurants Serves Up Fresh Catalysts for a Stock Price RallySoFi Is Bypassing the Banking Bottleneck With Stablecoin SettlementSuper Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
